RxDoctor Payments DataLook up a doctor →

David Kiken, MD

Procedural Dermatology · Florham Park, NJNPI 1801004114

Payments from drug & device makers

$4,733in general payments, 2019–2025

Across 388 payments — averaging $12.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Galderma Laboratories, L.p.$1K
  • AbbVie$695
  • Mayne Pharma Commercial LLC$376
  • Sun Pharmaceutical Industries Inc.$210
  • VYNE Pharmaceuticals Inc.$201
  • plus $878 from 14 others

What the payments were for

  • Food & beverage$4,01685%
  • Education$71715%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,733 in reported general payments places this provider in the 75th percentile of 22 procedural dermatology providers in New Jersey.

See all procedural dermatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$2,627,667
Medicare patients
910
Services billed
14,907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab12$159,275
Dupixent PenDupilumab18$67,895
Dupixent SyringeDupilumab15$60,055
Mupirocin523$6,541
Ketoconazole230$4,598
Halobetasol Propionate62$4,134
Clobetasol Propionate74$3,610
Fluocinonide66$2,918
Metronidazole39$2,213
Tretinoin25$1,956
Desonide29$1,673
Betamethasone Valerate25$1,628
Triamcinolone Acetonide178$1,218
Doxycycline Hyclate89$1,201
Tacrolimus13$840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$1,254$159,27512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 22 procedural dermatology providers in New Jersey.

Other procedural dermatology in Florham Park

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →